Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)
NCT01198509 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 178
Last updated 2015-01-13
Summary
Rheumatoid arthritis (RA) is an inflammatory form of arthritis that causes joint pain and damage. RA attacks the lining of the joints (synovium), causing swelling that can result in aching and throbbing, and eventually deformity. Even though there have been many advances in the treatment of RA, psoriatic arthritis (PsA), and other inflammatory arthritis, doctors still do not know what causes this inflammation in joints. It is likely that RA occurs as a result of a complex combination of factors, including a person's genes; lifestyle choices, such as smoking and diet; and things in a person's environment, including bacteria or viruses. This study investigates the hypothesis that bacteria living in a person's mouth and/or intestinal tract are responsible, at least in part, for the development of Rheumatoid Arthritis. The investigators believe that by killing those bacteria with antibiotics, they might be able to understand how the immune system works and, maybe, what causes RA.
Conditions
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Periodontal Disease
Interventions
- DRUG
-
doxycycline
doxycycline - 100 mg twice per day, for 2 months
- DRUG
-
vancomycin, 250 mg four times a day, for 2 weeks
Sponsors & Collaborators
-
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
collaborator NIH -
Memorial Sloan Kettering Cancer Center
collaborator OTHER - lead OTHER
Principal Investigators
-
Steven B. Abramson, MD · NYU Langone Health
-
Jose U. Scher, MD · NYU Langone Health
Study Design
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2010-01-31
- Primary Completion
- 2013-01-31
- Completion
- 2013-01-31
Countries
- United States
Study Locations
More Related Trials
-
Efficacy and Safety of Fecal Microbiota Transplantation in Peripheral Psoriatic Arthritis
NCT03058900 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of Fecal Microbiota Transplantation in Patients With Rheumatoid Arthritis Refractory to Methotrexate
NCT03944096 ·Status: UNKNOWN ·Phase: PHASE2
-
Probiotics in Adults With Rheumatoid Arthritis
NCT07304505 ·Status: RECRUITING ·Phase: NA
-
A Study of ARRY-371797 in Patients With Rheumatoid Arthritis
NCT00729209 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive
NCT00264537 ·Status: COMPLETED ·Phase: PHASE3
-
The Efficacy of Fecal Microbiota Transplatation on Axial Spondyloarthritis Patients Resistant to Conventional Treatment
NCT05654753 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis
NCT02277574 ·Status: COMPLETED ·Phase: PHASE1
-
Drug-Drug Interaction Study of MRA in Patient With Rheumatoid Arthritis (RA)
NCT00144560 ·Status: COMPLETED ·Phase: NA
-
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)
NCT00891020 ·Status: COMPLETED ·Phase: PHASE3
-
Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate
NCT00628095 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety and Pharmacokinetics Study in Participants With Rheumatoid Arthritis
NCT00380744 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis
NCT01026519 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Antibiotic Treatment for Reactive Arthritis Caused by Chlamydia Bacteria
NCT00351273 ·Status: COMPLETED ·Phase: PHASE3
-
Microbiota Analysis to Predict Outcomes of Rheumatoid Arthritis Patients Treated With JAK-inhibitor
NCT04530305 ·Status: UNKNOWN
-
An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.
NCT00750880 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients
NCT01061736 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Non-Interventional Study in Patients With Rheumatoid Arthritis Who Are Treated With RoActemra/Actemra (Tocilizumab)
NCT01893255 ·Status: WITHDRAWN
-
Clinical Pharmacology Study of MRA in Patient With Rheumatoid Arthritis (RA) With Renal Impairment
NCT00144573 ·Status: COMPLETED ·Phase: NA
-
The Role of Microbiome on Biological Therapy Efficacy in axSpA and RA
NCT04973787 ·Status: UNKNOWN
-
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy
NCT00973479 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis
NCT01941095 ·Status: COMPLETED ·Phase: PHASE3
-
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
NCT02097524 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Effect of Tocilizumab on Signs and Symptoms in Patients With Rheumatoid Arthritis
NCT00848120 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy
NCT02001987 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis
NCT00109408 ·Status: COMPLETED ·Phase: PHASE3